Galderma 보도자료

2022년 2월 18일 16:28

Karen L. Ling joins Galderma’s Advisory Committee

Galderma, the world’s largest independent dermatology company, announced today that Karen L. Ling will join its Advisory Committee, effective March 1, 2022. Karen Ling has a tremendous track record in executive roles at AIG, Allergan, Merck and Wy...

2022년 1월 5일 17:20

Galderma Successfully Completes Acquisition of ALASTIN Skincare®

Galderma, the world’s largest independent dermatology company, announced today that it has received antitrust clearance from the U.S. authorities and has completed the acquisition of ALASTIN Skincare®, Inc. (“ALASTIN”), a specialty aesthetics comp...

2021년 12월 8일 10:05

Maria Teresa Hilado to Join Galderma’s Advisory Committee

Galderma, the world’s largest independent dermatology company, announced today that Maria Teresa “Tessa” Hilado will join its Advisory Committee, effective January 1, 2022. Ms. Hilado currently serves on the board of directors at Campbell Soup Com...

2021년 12월 7일 09:35

Galderma Announces New Data Demonstrating the Positive Anti-inflammatory Effect and Mode of Action of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

Galderma today announced that the Journal of Allergy and Clinical Immunology has published gene expression data that demonstrate the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo No...

2021년 11월 30일 10:15

Galderma to Acquire Award-winning ALASTIN Skincare® Enhancing Its Integrated Dermatology Platform to Continue Delivering the Best Experience to Patients

Galderma, the world’s largest independent dermatology company, announced that it has signed a definitive agreement to acquire ALASTIN Skincare®, Inc. (“ALASTIN”), a specialty aesthetics company dedicated to developing innovative and clinically-tes...

2021년 9월 30일 17:30

RESTYLANE®, the Original Stabilized Hyaluronic Acid Filler, Celebrates 25 Years of Unmatched Achievement

Galderma, the world’s largest independent dermatology company, today marks the 25th anniversary of RESTYLANE®. The original non-animal stabilized hyaluronic acid filler restores, enhances and refreshes the youthful-looking appearance of the skin. ...

2021년 9월 30일 11:30

Galderma Presents New Nemolizumab Data at EADV Reinforcing Rapid Onset of Action and Consistent Relief of Symptoms for People With Prurigo Nodularis and Atopic Dermatitis

Galderma today announced the presentation of new phase 2 data supporting the efficacy of its investigational monoclonal antibody, nemolizumab, at the virtual 30th EADV congress, taking place between 28 September and 2 October 2021. Results from tw...

2021년 9월 24일 09:20

Galderma Announces Exclusive Agreement With Sofregen to Develop the Next Generation of Biostimulator Fillers Using Silk-Based Technology

Galderma, the world’s largest independent dermatology company, and Sofregen Medical, Inc., a medical device company pioneering the use of silk protein for tissue building and regeneration, announced today they have signed a co-development and opti...

2021년 9월 10일 15:50

Galderma to Present New Data From Leading Aesthetics Portfolio and Launch* RESTYLANE® EYELIGHT™ at AMWC 2021

Galderma today announced new results from its robust pipeline and portfolio of dermal fillers and toxin injections. Eleven e-posters from Galderma-sponsored and investigator-initiated trials have been accepted at the upcoming Aesthetic & Anti-Agin...

2021년 6월 29일 10:15

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization ...

2021년 4월 8일 18:36

Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis

Galderma today announced that the Journal of the European Academy of Dermatology and Venereology (JEADV) has published full results from a post-hoc analysis of the phase 2b study of its investigational therapy, nemolizumab, in adult patients with ...

2021년 3월 4일 17:58

Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe

Galderma today announced a European re-launch of Sculptra® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with ...

2020년 12월 2일 09:08

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the duration of effect and the efficacy and safety of a single dose of Dysport® (abobotulinumtoxinA) for Injection (50U, 75U, 100U or 125U) versus p...

2020년 10월 12일 20:30

Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting

Galderma today announced the presentation of data from clinical trials of its aesthetic solutions and pipeline in five abstracts at the virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting. The company also announced that i...

2020년 10월 12일 20:30

갈더마, ‘ASDS 2020 연례 학회’서 새로운 에스테틱 솔루션 및 파이프라인 뒷받침하는 초록 5건 발표

갈더마(Galderma)가 온라인으로 진행되는 ‘2020 미국 피부 외과 학회(American Society for Dermatologic Surgery, 약칭 ASDS) 연례 학술대회’에서 5건의 초록 발표를 통해 자사의 에스테틱 솔루션과 파이프라인의 임상시험 데이터를 공개한다고 9일 발표했다. 갈더...

2020년 2월 20일 17:50

Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from moderate-to-severe prurigo nodularis (PN). PN is...

2019년 12월 9일 17:47

Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis

Galderma today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with prurigo nodularis. Prurigo nodularis is...

2019년 10월 10일 17:26

Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis

Galderma, a global leader focused on meeting the world's increasing skin health needs, announced that it has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigational therapy in adult patients with moderate-t...

2019년 3월 11일 10:00

Galderma Presented Final Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis at the 2019 American Academy of Dermatology Annual Meeting Late-Breaking Session

Galderma, Nestlé Skin Health’s medical solutions business, presented the final results from a Phase 2b dose-ranging study of nemolizumab, an investigational therapy in adult patients with moderate-to-severe atopic dermatitis (AD), at the late-brea...

2018년 11월 1일 14:20

Galderma, Nestlé Skin Health’s Medical Solutions Business, Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis

Galderma, Nestlé Skin Health’s medical solutions business, today announced positive results from a Phase 2b dose-ranging study of nemolizumab in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. Nemo...

2018년 11월 1일 14:20

네슬레 스킨헬스의 의료솔루션 사업부문 갈더마, 중간/증증 아토피성 피부염 환자들을 대상으로 한 2b 상 임상실험에서 긍정적 결과 냈다고 발표

네슬레 스킨헬스(Nestlé Skin Health)의 의료솔루션 사업부문 갈더마(Galderma)가 심각한 만성 증상을 나타내는 습진의 일종인 아토피성 피부염(AD) 중간 및 중증 성인환자들을 대상으로 네모리주맙(nemolizumab) 용량확인 연구 2b상 임상실험에서 긍정적인 결과를 ...

2017년 1월 10일 16:50

Market Research Proves Success of Galderma’s Harmony Programme for Aesthetic Practice

Market research concludes that Galderma’s Harmony Programme for aesthetic Health Care Professionals (HCPs) significantly increases patient satisfaction. Using Harmony resulted in more returning patients and led to an increase in full face treatmen...

2017년 1월 10일 16:50

갈더마의 미용 시술용 하모니 프로그램 효과 밝혀져

시장조사결과에 따르면 미용성형 의료전문가들(HCPs)을 위한 갈더마(Galderma)의 하모니 프로그램(Harmony Programme) 도입 이후 환자들의 만족도가 월등히 높아진 것으로 밝혀졌다. 프로그램 도입 후 재원 환자의 수 뿐만 아니라 안면 전체 치료 환자 수도 증가한 ...

2016년 10월 7일 15:25

Galderma Campaign “Proof in Real Life”: Patients Tell their Stories One Year Later

In 2015, Sharon Stone, signed on to the “Proof in Real Life” campaign to help Galderma challenge common misconceptions of aesthetic treatments. Galderma & Sharon Stone unveiled the natural-looking results of Restylane fillers and Restylane Skinboo...

2015년 12월 2일 11:30

The Asian Acne Board and Galderma Join Forces to Improve Understanding and Management of Acne

The Asian Acne Board (AAB) and Galderma are inviting candidates to apply for a research grant of 10,000 USD to contribute to the improvement of best practices in the management of acne. The AAB research grant with the unrestricted support of Galde...

Galderma

Galderma 보도자료

회사 보도자료 구독